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recently found to underlie a different
hereditary tumor syndrome, familial
leiomyomatosis and renal cell cancer
(Eng et al., 2003). Isaacs et al. report in
this issue that decreased activity of FH
inhibits HIF hydroxylase activity (Isaacs
et al., 2005). So there is an emerging pic-
ture that TCA cycle defects can impact
key enzyme reactions by altering the
concentration of fumarate and succinate.
This is an alternative to the hypothesis
that loss of function of FH or SDH sub-
units acts through mitochondrial dys-
function and increased generation of
reactive oxygen species (Eng et al.,
2003). So far, studies have focused on
HIF hydroxylases, but these form only
one branch of an extensive family of 
2-oxoglutarate-dependent oxygenases
whose activity might be modulated.
In any event, a spotlight is now on
EglN3/PHD3, and it will be interesting to
determine if mutations in this gene
occur in pheochromocytoma, or in other
tumors. An important challenge is iden-
tifying the link between the enzyme and
apoptosis, which presumably involves
hydroxylation of a protein other than
HIF.
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P R E V I E W S
Metastasis, the spread of cancer
from the primary site of tumor growth to
other organs, is the leading cause of can-
cer-related morbidity and mortality. It is a
sequential process, contingent on tumor
cell acquisition of the following capabili-
ties: invasion, survival and arrest in the
bloodstream, extravasation, and colo-
nization at a distant site. Layered onto
these general requirements of metasta-
sis, tumor cells may acquire the capacity
to preferentially colonize distinct organs.
Over a century ago, Paget compared
metastatic tumor cells to widely dissemi-
nated seeds, which will grow only on fer-
tile soils (Paget, 1889). This vision
propelled the hypothesis that tumor cell-
host interactions serve as the prime con-
tributor to organ-specific metastasis. An
understanding of metastatic colonization,
both general and organ specific, may be
key to the development of antimetastatic
therapies; the final step of colonization
has not been completed in the majority of
cancer patients at the time of diagnosis
and surgery and is therefore amenable to
therapeutic targeting (Steeg, 2003).
Tissue tropism or organ-specific
homing of cancer cells depends on both
the histology and the stage of cancer.
Ocular melanomas stand as a stunning
example of this tropism, metastasizing
preferentially to the liver. Other cancers,
such as breast, metastasize to multiple
sites, most commonly lung and bone tis-
sue and with less frequency the liver and
the adrenal glands. Several factors are
thought to influence the site of cancer
metastasis, and these include (1) the
pattern and direction of blood flow from
the primary tumor, (2) mechanical trap-
ping of tumor cells at a secondary site by
small capillary beds, (3) tumor cell adhe-
sion at a secondary site by the expres-
sion of appropriate cell surface proteins,
Metastasis gets site specific
Organ-specific homing and colonization of cancer cells are important and interesting features of metastasis. Molecular
programs that contribute to this tropism may be elucidated through gene expression profiling with DNA microarrays. Using
experimentally derived breast cancer cells that home specifically to bone or to lung, several investigators have concluded
that distinct alterations in gene expression underlie metastasis to these sites. Minn et al. (2005) report a set of genes
involved in lung-specific metastasis of breast cancer; the authors have determined the functional contribution of several
genes to the metastatic cascade, as well as the relevance of these genes to human disease.
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and finally, (4) the microenvi-
ronment of the secondary site,
which can create a permissive
site for metastatic colonization
of tumor cells.
Based on the classical
assumption that organ-specific
metastasis results from alter-
ation of distinct genetic pro-
grams and pathways, several
recent studies have attempted
to comprehensively define the
molecular players that con-
tribute to breast cancer tissue
tropism to either the lung or the
bone (Kang et al., 2003; Lee et
al., 2003; Montel et al., 2005).
The Massague lab established
a bone metastasis model
system by harvesting bone
metastases of the human
MDA-MB-231 breast carcino-
ma cell line from mice, expand-
ing the cells in culture, and
reinjecting them into mice
(Kang et al., 2003). Microarray
analysis of the parental versus
a highly bone-metastatic line identified
102 differentially expressed genes. To
test their functional contribution to bone
metastasis, a limited number of these
genes, encoding proteins that were
largely membrane bound or secreted
and thus potentially influencing tumor-
host interactions, were transfected into
the parental cell line. Overexpression of
the chemokine receptor CXCR4 signifi-
cantly decreased bone metastasis-free
survival in vivo, while Interleukin 11 (IL-
11), which reportedly stimulated osteo-
clast formation among other functions,
did not. The lab then took the bold step
of analyzing gene combinations, report-
ing that IL-11 in combination with
Osteopontin (OPN) and connective tis-
sue growth factor (CTGF) enhanced
bone metastasis in vivo.
In the current issue of Nature, Minn
et al. present elegant work that provides
the next chapter in this story (Minn et al.,
2005). Through a similar in vivo selection
procedure, they established an MDA-
MB-231-derived cell line, called LM2,
that specifically colonizes the lungs.
Microarray analysis revealed that the
gene expression profile of the LM2 cells
is distinct from the parental cells, with 95
genes exhibiting differential expression.
This list was trimmed, through hierarchi-
cal cluster analysis with a spectrum of
random, single-cell progeny lines, also
derived from MDA-MB-231 cells that
exhibit varying affinities for metastasis to
the lung, to 54 genes and dubbed the
“lung metastasis signature.”
The authors then determined the
functional contribution of the genes in
their signature to the process of lung
metastasis. They chose nine genes from
this signature, again selecting for genes
that encode for membrane-localized or
secreted proteins. Only overexpression of
the transcription factor ID1 by itself pro-
moted lung metastasis of MDA-MB-231,
which raises the question “is it a regulator
of other genes within the signature?” In
the reciprocal experiment, knockdown
expression of three genes, ID1, the
Interleukin 13 receptor IL13RA2, and 
the vascular cell adhesion molecule
(VCAM1), significantly reduced lung colo-
nization of the LM2 cells. Lending support
to the notion that metastasis is a complex,
multipathway process, transfection of
combinations of genes was able to
enhance lung colonization in the parental
line, including the combination of the
chemokine ligand CXCL1, Epiregulin
(EREG), and COX2, none of which were
significantly active as single gene trans-
fectants. It should be noted, however, that
the lung is the most common site of
metastasis in most mouse assays, and
that many other genes have been studied
in this context on an individual basis. The
degree to which these other genes medi-
ate lung-specific metastasis is unknown.
Nor is it known to what extent
the genes identified in the MDA-
MB-231 model system are
specific for bone or lung metas-
tases in other model systems.
The authors did demonstrate
that the genes unique to the
“lung metastasis signature” did
not prompt bone metastasis,
although metastasis to other
organs was not assessed. Ten
genes were found to overlap in
their expression analyses of
bone and lung metastasis, and
these included MMP1 and
CXCR4. Several studies using
other model systems have
implicated the chemokine
receptor CXCR4 in homing to
both the lung and the bone
(Muller et al., 2001). The data
suggest that distinct sets of
genes regulate homing to the
lung and the bone, but some
genetic components are shared
(Figure 1).
The origin of metastases
has been hotly debated, with at least two
hypotheses posited. Whereas Fidler and
colleagues contend that metastatically
competent cells represent rare, preexist-
ing variants within a primary tumor (Fidler
and Kripke, 1977), several microarray
studies of primary tumors have conclud-
ed that gene expression signatures pre-
sent in the bulk of primary tumor cells
may predict metastatic potential (Sorlie et
al., 2001; van ’t Veer et al., 2003). One
potential reason for the predominance 
of metastasis-related genes in primary
tumors is that they confer a selective
advantage by enhancing tumorigenicity
as well; thus it was hypothesized that
such genes may coordinately promote
growth at primary and secondary sites.
Minn et al. silenced putative lung-specific
metastasis genes with shRNA in the LM2
lines and injected the cells into the flanks
of mice to determine if they coordinately
promoted primary tumor growth (Minn et
al., 2005). Only knockdown of the ID1
gene reduced tumorigenicity; the remain-
der of the lung-specific genes were
metastasis specific.
Minn et al. also analyzed the expres-
sion of their lung-specific metastasis 
signature in a cohort of 82 breast carcino-
mas with 10 years of clinical course fol-
low-up (Minn et al., 2005). Expression of
the lung metastasis signature by primary
tumors was correlated with poor survival
from lung-specific metastasis, but not
P R E V I E W S
Figure 1. Schematic of breast tumor cell progression as it pertains
to site-specific metastasis and colonization to bone and lung tissue
Normal mammary epithelium undergoes oncogenic transforma-
tion, and metastasis to distant organs is characterized by the
expression of distinct sets of genes. The Venn diagram represents
genes that contribute to homing and metastatic colonization, with
genes involved in bone-specific metastasis and lung-specific
metastasis and genes that are shared between the two common
metastatic sites indicated.
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bone-specific metastasis. The impor-
tance of these data, in our opinion, lies
not with the magnitude of their prognostic
significance. Breast cancer is now replete
with prognostic gene signatures, from
young women, primary tumors versus
metastases, classes of tumors, wound
signatures, etc. (Chang et al., 2005;
Sorlie et al., 2001; van ’t Veer et al.,
2003). These data confirm the relevance
of the lung-specific genes identified in a
single model system to the heterogeneity
of human disease.
Using microarray expression analy-
sis of primary tumors from 82 patients
from Memorial Sloan-Kettering Cancer
Center, the predictive value of each of
the 54 genes within their experimentally
derived signature was determined using
a Cox proportional hazards regression
model. Relatively few of the functional
lung-specific genes were significant. Of
the genes modulating lung-specific
metastasis as single transfectants, the 
p values were all nonsignificant
(0.569–0.833). Of the genes analyzed in
combination experiments, MMP1 and
CXCL1 retained lung-specific prognostic
significance, but others, including COX2,
SPARC, and EREG, did not. Put simply,
the functional genes were not the most
prognostic genes. It will be of interest to
determine whether the most highly prog-
nostic genes, such as latent TGF-β bind-
ing protein LTBP1, the Fascin homolog
FSCN1, and the angiopoietin-like protein
ANGPTL4, are functionally involved in
lung-specific metastasis.
Minn et al. identified several potential
players in the process of breast cancer
metastasis to lung, but a detailed mech-
anism of organ-specific homing and col-
onization has yet to be established. The
identification and validation of organ-
specific metastatic pathways should lead
to targeted therapeutics for these devas-
tating diseases.
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A series of complex and orchestrated
changes in chromosome structure are
required to ensure the proper segrega-
tion of genetic material during cell divi-
sion. A direct consequence of the double
helical structure of DNA is that, after DNA
replication during S phase, duplicated
sister DNAs become topologically entan-
gled or catenated (Wang, 2002). Sister
chromatids continue to maintain a close
association throughout G2 phase. Then,
a signal at the onset of anaphase causes
disruption of the linkage between sister
chromatids, allowing them to be separat-
ed and pulled to opposite poles of the
cell. However, a process called DNA
decatenation needs to take place to sep-
arate chromosomes that have become
entangled. This process involves DNA
strand breakage and rejoining, and
requires the enzyme Topoisomerase IIα
(TopIIα) (Wang, 2002). Cells monitor the
catenation of chromatids, and when
these are insufficiently disentangled, the
decatenation checkpoint is activated,
arresting cells in metaphase (Deming et
al., 2001). This checkpoint is separate
from the response to DNA damage
(Skoufias et al., 2004) and may be inacti-
vated in some cancers (Nakagawa et al.,
2004), leading to inappropriate cell cycle
progression, chromosome breakage, and
genomic instability.
BRCA1 is a key regulator of DNA
repair and the cell cycle in higher eukary-
otic cells, and dysfunction leads to pre-
disposition to breast and a variety of
other cancers (Wooster and Weber,
2003). BRCA1 is required for the efficient
repair of double-strand DNA breaks
(DSBs) by homologous recombination,
and BRCA1 deficiency leads to the uti-
Oh what a tangled web it weaves: BRCA1 and DNA decatenation
BRCA1 has significant roles in DNA repair and cell cycle checkpoint control, and is important in the maintenance of
genomic stability. Defects in these pathways likely underpin the cancer susceptibility of BRCA1 mutation carriers. Now, a
new function for BRCA1 in DNA decatenation—removing the tangles introduced into chromosomes as a consequence of
DNA replication—is suggested in a new paper by Lou et al. (2005) in Nature Structural and Molecular Biology. Ineffective
DNA decatenation may lead to chromosome breakage and inappropriate repair, adding to the roll call of defects in BRCA1
mutant cells.
